240 related articles for article (PubMed ID: 21245100)
1. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Sabnis GJ; Goloubeva O; Chumsri S; Nguyen N; Sukumar S; Brodie AM
Cancer Res; 2011 Mar; 71(5):1893-903. PubMed ID: 21245100
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors and xenograft studies.
Chumsri S; Sabnis GJ; Howes T; Brodie AM
Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
6. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Swami S; Krishnan AV; Wang JY; Jensen K; Peng L; Albertelli MA; Feldman D
Horm Cancer; 2011 Jun; 2(3):190-202. PubMed ID: 21686077
[TBL] [Abstract][Full Text] [Related]
8. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
Brodie AM; Chumsri S; Sukumar S; Sabnis GJ
Horm Mol Biol Clin Investig; 2011 Mar; 5(2):97-103. PubMed ID: 25961245
[TBL] [Abstract][Full Text] [Related]
9. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
[TBL] [Abstract][Full Text] [Related]
10. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
Sabnis G; Goloubeva O; Gilani R; Macedo L; Brodie A
Mol Cancer Ther; 2010 Jan; 9(1):46-56. PubMed ID: 20053764
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
14. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
15. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
16. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
18. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Dabydeen SA; Kang K; Díaz-Cruz ES; Alamri A; Axelrod ML; Bouker KB; Al-Kharboosh R; Clarke R; Hennighausen L; Furth PA
Carcinogenesis; 2015 Jan; 36(1):122-32. PubMed ID: 25421723
[TBL] [Abstract][Full Text] [Related]
20. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
